Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010 Mon, November 30, 2020, 6:30 AM MST Compared to recombinant human IL-12, SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile that was similar to IgG antibodies
SON-1010 continues to be well tolerated at doses far exceeding levels expected in potential future clinical trials, without producing detectable cytokine imbalances
Analysis of Interferon-? levels, a key biomarker of antitumor activity, suggest potent on-target pharmacodynamic (PD) effects
RE JUST IN: $SONN 3 Penny Stocks To Watch After Trump's Emergency Plasma Authorization
Convalescent Plasma Stocks To Watch Penny stocks shift in an instant and that could be the case for a few companies this week.
Over the weekend, U.S. President Donald Trump announced the emergency authorization of convalescent plasma for COVID-19.
https://www.sonnetbio.com/news-media/press-releases Nov 30, 2020 8:30am EST Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010 Sep 01, 2020 8:30am EDT Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB)